Document is current
Any future updates will be listed below
-
Authors
Naito, Yoichi https://orcid.org/0000-0002-8490-9064
Iwagami, Shiro
Doi, Toshihiko
Takahashi, Tsuyoshi
Kurokawa, Yukinori
-
Funding
Funding for this research was provided by:
Taiho Pharmaceutical
- License Information
-
More Information
Article History
Received: 15 October 2024
Accepted: 15 February 2025
First Online: 28 February 2025
Declarations
:
: Yoichi Naito received grants or contracts from AbbVie Inc., Ono Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., Pfizer Japan Inc., Nippon Boehringer Ingelheim Co., Ltd., Eli Lilly Japan K.K., Eisai Co., Ltd., AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., and Bayer Yakuhin, Ltd., and received honoraria for lectures from AstraZeneca K.K., Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Guardant Health Japan Corp., Takeda Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Novartis Pharma K.K., Pfizer Japan Inc., Chugai Pharmaceutical Co., Ltd., PDR Pharma Inc., Nippon Kayaku Co., Ltd., Taiho Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., Bayer Yakuhin, Ltd., Daiichi Sankyo Co., Ltd., MSD K.K. Shiro Iwagami has no conflicts of interest to disclose. Toshihiko Doi received grants and contracts from PRA Health Sciences K.K., MSD K.K., Daiichi Sankyo Co. Ltd., Amgen K.K., Taiho Pharmaceutical Co., Ltd., GlaxoSmithKline PLC., Ono Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Nippon Boehringer Ingelheim Co., Ltd., Pfizer Japan Inc., Bristol-Myers Squibb K.K., AbbVie Inc., Eisai Co., Ltd., RIN Institute Inc., Chugai Pharmaceutical Co., Ltd., and Shionogi & Co., Ltd., and received consulting fees from Sumitomo Pharma Co., Ltd., Oncolys BioPharma Inc., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., NanoCarrier Co., Ltd., Rakuten Medical Inc., Otsuka Pharmaceutical Co., Ltd., Kaken Pharmaceutical Co., Ltd., Kyowa Kirin, Shionogi & Co., Ltd., PRA Health Science K.K., A2 Healthcare Corporation, Noil-Immune Biotech Inc., and Mitsubishi Tanabe Pharma Corporation, and received honoraria for lectures from Daiichi Sankyo Co., Ltd., and participated on an advisory board of Gilead Sciences K.K., Pfizer Japan Inc., Amgen K.K., and Zymeworks Inc. Toshihiko Doi is also an Editorial Board Member (Associate Editor) of Cancer Science. Tsuyoshi Takahashi received honoraria for lectures from Pfizer Japan Inc., Bayer Yakuhin, Ltd., Taiho Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., and Sawai Pharmaceutical Co., Ltd., and received payment for expert testimony from Taiho Pharmaceutical Co., Ltd. Yukinori Kurokawa received grants and contracts from Taiho Pharmaceutical Co., Ltd., AstraZeneca K.K., MSD K.K., Yakult Honsha Co., Ltd., and Ono Pharmaceutical Co., Ltd., and received honoraria for lectures from Taiho Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Nippon Kayaku Co., Ltd., Ono Pharmaceutical Co., Ltd., Lilly Japan K.K., and Kaken Pharmaceutical Co., Ltd.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Additionally, the protocol and its amendments were approved by the institutional review boards before the initiation of the study. No animal studies were conducted.
: All patients provided written informed consent.
